Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Candel Therapeutics (CADL) FCF Margin (2020 - 2022)

Candel Therapeutics' FCF Margin history spans 3 years, with the latest figure at 21590.32% for Q4 2022.

  • On a quarterly basis, FCF Margin rose 7410968.0% to 21590.32% in Q4 2022 year-over-year; TTM through Dec 2022 was 25393.55%, a 109759.0% decrease, with the full-year FY2022 number at 25190.4%, down 113740.0% from a year prior.
  • FCF Margin hit 21590.32% in Q4 2022 for Candel Therapeutics, up from 28512.9% in the prior quarter.
  • Over the last five years, FCF Margin for CADL hit a ceiling of 4119.35% in Q3 2020 and a floor of 95700.0% in Q4 2021.
  • Historically, FCF Margin has averaged 27601.94% across 3 years, with a median of 23811.29% in 2021.
  • Biggest five-year swings in FCF Margin: plummeted -8014194bps in 2021 and later soared 7410968bps in 2022.
  • Tracing CADL's FCF Margin over 3 years: stood at 15558.06% in 2020, then tumbled by -515bps to 95700.0% in 2021, then surged by 77bps to 21590.32% in 2022.
  • Business Quant data shows FCF Margin for CADL at 21590.32% in Q4 2022, 28512.9% in Q3 2022, and 24135.48% in Q2 2022.